Subtitle
Major UK trial finds microaxial flow pumps don’t improve outcomes for patients undergoing complex heart procedures, potentially reshaping cardiac care protocols.
Cardiologists across the NHS are reviewing their treatment protocols after a major UK study questioned the effectiveness of a widely-used heart support device. The CHIP-BCIS3 trial, published in the New England Journal of Medicine, examined whether microaxial flow pumps actually improve outcomes for patients undergoing complex heart procedures.
The research focused on percutaneous coronary intervention (PCI) – a procedure where doctors insert tiny tubes called stents to open blocked heart arteries. For the most challenging cases, many hospitals routinely use microaxial flow pumps to support the heart during the procedure.
The Trial Results
But the findings tell a different story. Patients who received the microaxial flow pump support didn’t experience fewer major complications compared to those who received standard care alone. The study tracked serious outcomes including heart attacks, strokes, kidney problems requiring dialysis, and deaths.
This challenges current practice in many cardiac centres. The pumps, which are inserted through blood vessels to help the heart pump blood during complex procedures, have been considered a safety net for high-risk patients.
The trial involved patients undergoing what doctors call “complex PCI” – procedures on severely blocked or difficult-to-reach arteries where the risk of complications runs higher than standard heart procedures.
What Doctors Are Saying
The research represents one of the largest controlled studies of its kind. Previous smaller studies had suggested the pumps might offer protection, but trial involving multiple hospitals found no significant benefit.
Cardiac teams will now need to weigh up when these devices truly add value. The pumps aren’t without risks themselves – they can cause bleeding, blood clots, or damage to blood vessels during insertion.
The Bigger Picture
Heart disease remains the leading cause of death in England, with around 64,000 people dying from coronary heart disease each year. PCI procedures help thousands of patients annually, opening blocked arteries that could otherwise cause heart attacks.
For the most complex cases, doctors have relied on various support devices to reduce risks. This study suggests that for microaxial flow pumps specifically, the benefits may not outweigh the potential complications.
The findings don’t mean these devices will disappear from cardiac units entirely. But they do suggest doctors need to be more selective about when to use them.
Source: @NEJM
Key Takeaways
- Microaxial flow pumps showed no benefit over standard care in complex heart procedures
- The CHIP-BCIS3 trial involved patients undergoing high-risk percutaneous coronary intervention
- Results may change how cardiac teams decide when to use heart support devices
What This Means for Kent Residents
If you or a family member needs complex heart treatment at Kent hospitals, your cardiac team will continue to use the most appropriate techniques for your specific situation. The study doesn’t affect emergency heart attack treatment or routine procedures – it specifically relates to planned complex interventions where doctors previously thought extra heart support was beneficial. Always discuss any concerns about heart procedures with your GP or consultant, and remember that NHS 111 is available for urgent health advice outside normal surgery hours.